Supplemental material
Open access
5,936
Views
21
CrossRef citations to date
0
Altmetric
Report
VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis
Sarah Lowa Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USAhttps://orcid.org/0000-0001-7587-6435
, Haixia Wua Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Kavita Jeratha Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Annette Tibollab Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Birgit Fogalb Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USAhttps://orcid.org/0000-0002-1682-7729
, Rebecca Conradb Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Deborah Webbc Immunology and Respiratory Diseases, Boehringer Ingelheim Pharmaceuticals Inc
, Margit MacDougallb Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Steven Kerrb Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Valentina Bergerb Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USAhttps://orcid.org/0000-0001-9597-3638
, Rajvee Daveb Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Jorge Villalonab Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Lynn Pantagesb Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Jennifer Ahlbergd Biotherapeutics Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USAhttps://orcid.org/0000-0002-2892-4163
, Hua Lid Biotherapeutics Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Diane Van Hooricke Project Management, Ablynx a Sanofi Company, Zwijnaarde, Belgium
, Cedric Ververkene Project Management, Ablynx a Sanofi Company, Zwijnaarde, Belgium
, John Broadwaterb Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Alisa Watermanb Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
, Sanjaya Singha Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USAhttps://orcid.org/0000-0002-9119-7966
& Rachel Kroe-Barretta Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USACorrespondence[email protected]
https://orcid.org/0000-0003-1413-1223
show allhttps://orcid.org/0000-0003-1413-1223
Article: 1709322
|
Received 27 Aug 2019, Accepted 20 Dec 2019, Published online: 10 Jan 2020
Related Research Data
A Genetic Risk Factor
Source:
Ovid Technologies (Wolters Kluwer Health)
Screening and Characterization Strategies for Nanobodies Targeting Membrane Proteins.
Source:
Elsevier
When binding is enough: nonactivating antibody formats.
Source:
Elsevier BV
Fractalkine/CX3CR1 and atherosclerosis.
Source:
Elsevier BV
Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris.
Source:
Elsevier BV
Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1)
Source:
(:unav)
Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion
Source:
Elsevier BV
Decreased atherosclerosis in CX3CR1–/– mice reveals a role for fractalkine in atherogenesis
Source:
American Society for Clinical Investigation
Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies®
Source:
MDPI AG
Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery.
Source:
Elsevier BV
CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival.
Source:
American Society of Hematology
Fractalkine Is Expressed in Early and Advanced Atherosclerotic Lesions and Supports Monocyte Recruitment via CX3CR1
Source:
Public Library of Science (PLoS)
Functional heavy-chain antibodies in Camelidae.
Source:
Elsevier
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.